Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a very rare disease that currently lacks genomic and genetic biomarkers to assist in its clinical management. We performed whole-exome sequencing (WES) of three BPDCN cases. Based on these data, we designed a resequencing approach to identify mutations in 38 selected genes in 25 BPDCN samples. WES revealed 37-99 deleterious gene mutations per exome with no common affected genes between patients, but with clear overlap in terms of molecular and disease pathways (hematological and dermatological disease). We identified for the first time deleterious mutations in IKZF3, HOXB9, UBE2G2 and ZEB2 in human leukemia. Target sequencing identified 29 recurring genes, ranging in prevalence from 36% for previously known genes, such as TET2, to 12-16% for newly identified genes, such as IKZF3 or ZEB2. Half of the tumors had mutations affecting either the DNA methylation or chromatin remodeling pathways. The clinical analysis revealed that patients with mutations in DNA methylation pathway had a significantly reduced overall survival (P ¼ 0.047). We provide the first mutational profiling of BPDCN. The data support the current WHO classification of the disease as a myeloid disorder and provide a biological rationale for the incorporation of epigenetic therapies for its treatment.
INTRODUCTION
Blastic plasmacytoid dendritic cell neoplasm (BPDCN), previously referred as 'blastic NK-cell lymphoma/leukemia' or 'agranular CD4 þ /CD56 þ hematodermic neoplasm', is a rare and aggressive hematologic disease derived from precursors of a specialized subset of dendritic cells, and hence, after some discussion, is considered a myeloid-related disease according to the 2008 WHO classification of myeloid neoplasms. [1] [2] [3] [4] [5] [6] [7] These tumor cells infiltrate skin, bone marrow, peripheral blood and lymph nodes [8] [9] [10] [11] and mainly affect elderly patients with the maximum incidence peaking at B65 years of age.
Diagnosis is based on the immunophenotype of the blast cells that are characterized by the expression of CD4, CD43, CD56, CD123, BDCA-2/CD303, TCL1 and CTLA. 12 In addition, immunohistochemical markers, such as SPIB, BDCA-4, IRF-8, BCL11A and CD2AP, have been recently reported as tools for BPDCN diagnosis. 12, 13 There are no established genetic biomarkers that assist in the clinical management of BPDCN. Preliminary results from molecular studies suggest that abnormalities of genes known to have a putative role in the prognosis on other hematological malignancies, such as CDKN2A/CDKN2B, TET2 and TP53, are frequently seen in BPDCN. 14, 15 The overall prognosis for BPDCN is remarkably poor. Lymphoidlike chemotherapy is the preferred treatment, however, most patient relapse, resulting in a median overall survival (OS) of 12-14 months. 16, 17 Only high-dose therapy followed by allogeneic stem cell transplantation can provide durable control in this otherwise fatal condition. 18, 19 We designed a study to discover BPDCN-associated mutations based on sequencing the complete exome of three tumors, matched with normal samples. The discovered mutations detected were then further studied in an expanded cohort. These efforts led to the identification of several important disease-associated mutations, the reconstruction of the genetic pathways underlying the BPDCN pathogenesis and revealed associations between genetic events and clinically important features of the disease.
PATIENTS AND METHODS

Patient samples
DNA samples for whole-exome sequencing (WES) were obtained from normal tissue (oral mucosa) and tumor bone marrow in three patients with BPDCN. Thirty-nine additional tumors were further included for the targeted resequencing analysis: 11 tumor samples came from bone marrow cells, and 28 samples from paraffin-embedded tissues. All samples were obtained at BPDCN diagnosis. The study was approved by the ethical research and animal care committee from the Institute of Health Carlos III (CEI PI 32_2009). Clinical characteristics of the patients are summarized in Supplementary Table 1 . DNA was extracted by the phenol-chloroform method and the quality and quantity of purified DNA was assessed by fluorometry (Qubit, Invitrogen, Life Technologies, Carlsbad, CA, USA) and gel electrophoresis.
WES and bioinformatic analysis
The preparation of shotgun libraries from the leukemic and non-leukemic genomic DNA obtained from the three patients followed the 'SureSelect Human All Exon Kit' protocol (Agilent Technologies, Santa Clara, CA, USA), covering 50 Mb of coding exons (B1.60% of the genome). One to three micrograms of high molecular weight genomic DNA from each sample was fragmented by acoustic shearing on a Covaris S2 instrument (Life Technologies, Carlsbad, CA, USA). Fractions of 150-300 bp were ligated to Illumina adapters and PCR-amplified for six cycles. For exon enrichment, 300 ng of library was hybridized to SureSelect Human All Exon Capture kit for 24 h at 65 1C. Biotinylated hybrids were captured, and the enriched libraries were completed by amplifying with 12 cycles of PCR. The resulting purified DNA library was applied to an Illumina flow cell for cluster generation and sequenced using the Illumina Genome Analyzer IIx (San Diego, CA, USA) generating 2 Â 76 bp, paired-end reads by following the manufacturer protocols.
Exome variant analysis and biological impact predictions were performed by RUbioSeq software 20 using default parameters for somatic variation analysis. In detail, sequencing data were first checked by FastQC for quality control checks on raw sequence data and then aligned to the human reference genome (GRCh37) using Burrows-Wheeler alignment. 21 That reads unmapped by Burrows-Wheeler alignment were realigned using BFAST. 22 Somatic variants were identified using the Unified Genotyper v2 available at the GATK. 23 For variant calling, we used GATK Unified Genotyper v2 applying the 'Discovery' genotyping mode and default parameters for filtering. Thus, SNPs available at dbSNP132 (hg19) and those reported by the 1000 Genomes Project were filtered out from VCF output files. The GATK QUAL field was employed for ranking selected somatic variants. The percentage of reads supporting the mutation of the total number of reads at a given position was taken as 20% in the tumor DNA, and 0.5% in normal DNA. 24 Biological impact predictions for detected variants were obtained from Ensembl Variant Effect Predictor. 25 In order to estimate the damaging character of the missense mutations, we used two different algorithms: SIFT and PolyPhen-2.
Ingenuity pathway analysis
Genes found to be mutated among the three cases subjected to ingenuity pathways analysis (IPA) (Ingenuity Systems, Redwood City, CA, USA) and used as a starting point for building biological networks.
Targeted resequencing
We designed a custom panel of 38 genes (Supplementary Table 3 ) using the SureDesign Tool (Agilent). Ion semiconductor sequencing on the Ion Torrent PGM was performed using the HaloPlex target enrichment system (Agilent) in 25 BPDCN tumors. Briefly, patients' DNAs were digested by a cocktail of restriction enzymes and hybridized to specific probes incorporating Ion Torrent-specific sequence motifs. Hybridized molecules were captured with magnetic beads, amplified using indexed primers, Additionally, FLT3-ITD detection was carried out by conventional PCR in all samples as previously reported. 26 
Sanger sequencing validation
We used PCR amplification and direct DNA sequencing to validate candidate variants. Because of the sensitivity of Sanger, sequence variants that were reported in less than 20% of the reads could not be included in this validation phase. The purified products were subsequently sequenced using the automatic sequencer ABI 3730xl (PE Applied Biosystems, Foster City, CA, USA). Data were analyzed with BioEdit Sequence Alignment Editor 7.0.5.3.
Statistical analysis
For survival analysis, only the 17 patients with complete follow-up clinical data were included. OS was calculated taking into account the first date of diagnosis of BPDCN to death of disease or to last follow-up. Kaplan-Meier method was used to estimate the distribution of OS and differences in survival between-groups were assessed using the log rank test with the SPSS v.19 software (SPSS, Chicago, IL, USA). A P-value of p0.05 was considered statistically significant.
RESULTS
Mutations in coding sequencing by WES
To improve our understanding of the genes involved in the pathogenesis and clinical evolution of BPDCN, WES was performed on matched tumor and normal samples from three individuals with this disease. WES and bioinformatic analysis were carried out according to the workflow in Figure 1a . In total, we found 509, 590 and 1505 somatic alterations in case 1, case 2 and case 3, respectively. Among them, 347 were intronic in case 1, 457 in case 2 and 961 in case 3, and therefore excluded from further analysis. To gain insight into the genes affected by the transformation process in BPDCN, we focused our research on the mutations that passed our quality control and were predicted to result in protein-coding changes, identifying a total of 85 mutations in 81 affected genes: 28 mutations in case 1, 8 in case 2, and 49 in case 3 (Table 1 and Supplementary Table 2 ). The distribution of numbers and categories of somatically acquired exonic mutations and indels is represented in Figure 1b . Unfortunately, when we crossed these 81 affected genes, we did not identify a common mutated gene between patients ( Figure 1c ). Of interest, however, we identified, for the first time, deleterious mutations in IKZF3 (IKAROS family zinc-finger 3-Aiolos), HOXB9 (homeobox B9), UBE2G2 (ubiquitin-conjugating enzyme E2G 2) and ZEB2 (zinc-finger E-box binding homeobox 2) in human leukemia.
A functional clustering analysis of the mutated genes, using IPA software, showed a substantial enrichment of pathways involved in dermatological diseases and conditions, genetic disorder and hematological disease, among others (Supplementary Figure 1) . Looking in detail at the list of mutated genes within the hematological disease pathway, we observed that they have functions involved in DNA methylation (TET1 and TET2), chromatin remodeling (ASXL1) and RNA splicing (U2AF1); all of which have previously been reported as mutated in myeloid neoplasms. These data suggested that BPDCN has a mutational profile similar to that of other well-defined myeloid leukemias. Therefore, we decided to use a targeted re-sequencing approach to study these three pathways as well as transcription factors, protein kinase and ubiquitination genes involved in myeloid malignancies in an extension cohort.
Screening for somatic mutations in regions recurrently altered in myeloid neoplasm by targeted next-generation sequencing To explore these findings, we applied a comprehensive and costeffective target resequencing approach to indentify mutations in the coding sequences of 38 selected genes, which are prone to harbor mutations involved in leukemogenesis (n ¼ 25) and have been identified in our previous analysis (n ¼ 13) (Supplementary Table 3 ). This panel is composed of genes from nine categories: DNA methylation (5 genes), chromatin remodeling (4 genes), transcription factors (10 genes), splicing machinery (5 genes), protein kinase activity (6 genes) and ubiquitination (4 genes), nucleophosmin (1 gene), RAS family (2 genes) and tumor suppressor (1 gene). We included a total of 39 BPDCN tumor DNAs of which, after quality control for library preparation, 25 cases were suitable for analysis. On average, 98% of reads mapped uniquely to the target sequences, and we obtained 93% mean target coverage with an average read depth of 471 reads per base.
After filtering out changes in the intronic regions and polymorphisms (present in dbSNP132), we identified a total of 141 variants in all sequenced exons of the 25 BPDCN patients, an average of 5.64 mutations per case. After discarding alterations in noncoding RNAs, the 5 0 or 3 0 untranscribed regions, and synonymous mutations, only 90 single nucleotide variants and indels resulted in an amino acid change, frameshift or stop codon (Supplementary Table 4 ). We selected 52 single nucleotide variants/indels, based on the variant frequency, for validation by Sanger sequencing and confirmed 91% of the variants. In addition, with this resequencing strategy, we were able to detect all the alterations found in the three patients studied by WES, confirming the suitability of the panel for discovering genetic defects in the extension cohort.
Based on the pathogenic alterations, we observed mutations in 29 genes and a mean of 3.6 mutations per case. The extreme cases were one patient with 7 and another two patients with no pathogenic alterations in the 38 studied genes (Figure 2a) . TET2 was the most frequently mutated gene (36%), followed by ASXL1 (32%), NRAS (20%) and NPM1 (20%), the IKAROS family (20%) and ZEB2 (16%). In TET2, we identified ten heterozygous variants (4 frameshift, 4 nonsense and 2 missense changes) spread across the coding exons of the gene in nine patients. The frameshift p.Ile490Tyrfs*14 was found in two individuals and one patient had two different TET2 mutations. ASXL1 presented heterozygous mutations, mostly clustered in exon 12, in six patients. However, two mutations were found in exon 11. The majority of ASXL1 mutations were frameshift (n ¼ 6). Alterations in the NPM1 gene were found in exons 6 and 12. One of them was homozygous and two were present in more than one individual. All the mutations observed in NRAS were single AA changes, with three being in the known codon 12 and only one in codon 146 (Table 2 ). These data are in line with the mutational profiles reported for acute myeloid leukemia and other myeloid neoplasms.
27
ZEB2 and IKZF3, transcription factors previously not reported as being mutated in human leukemias, were found to contain deleterious mutations in our BPDCN DNAs. ZEB2 codes for a zinc-finger/homeodomain protein that normally functions as a DNA-binding transcriptional repressor. We found two frameshift mutations and one single AA change in ZEB2 (Table 2) . Finally, IKZF3 and other members of the IKAROS family of genes were also Figure 1 . Identification of somatic exonic variants in BPDCN by WES. (a) Sequencing workflow and bioinformatics pipeline for identification of somatic mutations. After alignment of the sequencing reads from DNA samples of BPDCN and normal cells to the human reference genome, a series of filters were applied to discard reads that were not usable for the downstream purpose of somatic mutation discovery. Sequence variants fulfilling the additional criteria were subjected to Sanger sequencing validation; (b) distribution of the numbers and categories of somatically acquired exonic mutations and indels among the three cases studied; (c) Venn diagram showing that there is no common mutated gene between patients (exonic, frameshift, stop gain/loss and no synonymous mutations-deleterious; QC4200). Recurrently mutated genes and their interaction in BPDCN. (a) Twenty-five total cases of BPDCN were screened for somatic variants in 13 genes identified by WES and in 25 genes previously reported to be mutated in myeloid malignancies (a total of 38 genes). Mutations are represented in red. We observed mutations in 29 genes; among them, TET2 is the most frequently mutated (36%), followed by ASXL1 (32%), NRAS (20%) and NPM1 (20%), IKAROS family (20%) and ZEB2 (16%). (b) The circos diagram depicts the relative frequency and pairwise co-occurrence of mutations in the BPDCN patients. The length of the arc corresponds with the frequency of mutations in the first gene, and the width of the ribbon corresponds to the percentage of patients who also had a mutation in the second gene. Pairwise co-occurrence of mutations is denoted only once, beginning with the first gene in the clockwise direction. Mutations in TET1-2 and IDH1-2 are mutually exclusive, as previously reported in other myeloid malignancies. recurrently mutated in BPDCN. One patient had a frameshift mutation in IKZF1, another had a single AA change in IKZF2 and three patients had alterations in IKZF3: one single AA change and one frameshift in two cases. Twenty percent of our BPDCN patients harbored mutations in IKAROS family genes, suggesting a potential role of these genes in this specific type of myeloid leukemia (Supplementary Figure 2) .
Functional categorization of mutated genes
We used circus diagrams to assess patterns of mutual exclusivity and co-occurrence between sets of genes. We identify mutually exclusive alterations that affect TET1/2 and IDH1/2; TET1/2 and DNMT3A; and between IKAROS family genes. Additionally, mutations in ASXL1 and DNMT3A rarely co-occurred in our samples, with only one harboring mutation in both. A rare co-occurrence was also observed between the splicing genes with only one case having mutations in both SF3B1 and SRSF2 (Figure 2b and Supplementary Figure 3) . We also grouped mutations into larger sets or pathways and examined patterns of mutual exclusivity and co-occurrence between these groups (Figure 2a and Supplementary Figure 4) . Out of the 25 samples, 23 (92%) contained at least one mutation in one of the nine categories. The nine categories and how frequently they were mutated are: aberrant methylation (48%), chromatin remodeling (52%), transcription factors (44%), splicing machinery (36%), protein kinase activity (16%), ubiquitination (12%), nucleophosmin (20%), RAS family (28%) and tumor suppressor-TP53 (8%). Half of the tumors had mutations affecting the methylation profile and chromatin remodeling pathways, and 20% had mutations in genes in both pathways.
Clinical relevance of aberrant methylation genes mutations
The analysis of survival data from the study cohort revealed several significant differences among the patients. First, we found that the patients with mutations in genes in methylation pathways had a significantly reduced OS rate compared with individuals without mutations in these genes (median 11 months versus 79 months; P ¼ 0.047, Figure 3a) . On the other hand, patients with mutations in ETV6 (P ¼ 0.022), TP53 (P ¼ 0.003) and N/K RAS (P ¼ 0.015) had either a statistically significant worse prognosis (Supplementary Figure 5) or showed a trend in the same direction (P ¼ 0.073) when a mutation of IKZF1/2/3 was present. Taking into consideration the limited sample size, we also combined the subgroups based on the functional classes for the outcome of analysis. Among the combinations with clinical interest, the worst clinically significant changes were those affecting the RAS family, TP53 and other transcription factors (median 15 months versus 99 months for the non-mutated cases; P ¼ 0.013) (Figure 3b ). These data suggest that mutations in aberrant methylation genes represent a poor prognostic factor and are probably involved in the pathogenesis of BPDCN.
DISCUSSION
Because BPDCN is a rare disease that was recognized as a distinct entity only recently, information regarding genomic and genetic biomarkers is rather limited. Lucioni et al.
14 studied 21 BPDCN patients by comparative genomic hybridization arrays and found complete or partial chromosomal losses with common deleted regions involving the CDKN2A/CDKN2B, RB1, CDKN1B, LATS2 and IKZF1 loci. Jardin et al. 15 reported 54 and 38% of TET2 and TP53 mutations, respectively, in the 13 BPDCN individuals studied. In this study, we present, for the first time, a comprehensive analysis of BPDCN combining next-generation sequencing with clinical characteristics and clinical outcomes of 25 patients. Although we did not find a common alteration that could explain the pathogenesis of BPDCN in the three patients studied by WES, we identified deleterious mutations in IKZF3, HOXB9, UBE2G2 and ZEB2 for the first time in human leukemia and more common alterations such as TET1/2, ASXL1 and U2AF1 previously reported as mutated in other myeloid neoplasms.
The best test of the relevance of individual mutations for pathogenesis (in the absence of functional validation) is their recurrence in other samples or other cancers. TET2 mutations featured in our series appear similar to those observed in myeloid neoplasms: aberrations are mainly frameshift or nonsense and have been observed with the same frequencies (36-58%). 28 However, our TET2 and TP53 mutation frequency are lower compared with the BPDCN cases from Jardin et al. 15 Similar to other hematological malignancies, the relevance of TET2 mutations remains undetermined in this disease, which is characterized by a peculiar combination of various genomic alterations. Truncated exon 12 mutations in ASXL1 have recently been described in 11% of patients with myelodysplastic syndromes, 43% of those with chronic myelomonocytic leukemia, 7% with primary and 47% with secondary acute myeloid leukemia (AML). 29 The NPM1 mutations have been shown to be involved in 23.5% of AML patients and activating RAS mutations were found to be present in 10.7%. 30, 31 Notably, only one BPDCN case displayed JAK2 and other FLT3-ITD mutations, reinforcing that BPDCN and AML or myeloproliferative disorders may be genetically distinct. Pointing out to these differences, we found mutations in genes never shown to be involved in human leukemia. First, the IKAROS gene family encodes zinc-finger transcription factors that regulate gene expression via chromatin remodeling in lymphoid development and differentiation. In fact, IKZF1/2/3 mutations, present as deletions, are prevalent in acute lymphoblastic leukemia. 29, 32 As 20% of our BPDCN patients harbored mutations in IKAROS family genes, a potential role of these genes in normal or abnormal myelopoiesis should be considered. Secondly, although mutations in ZEB2 have not been reported in human cancer, ZEB2 protein interacts with several members of the SMAD protein family that have been shown to have important roles in normal and malignant hematopoiesis. Finally, a preliminary report indicated that ZEB2 was overexpressed in leukemia patients with MLL gene rearrangements. 33 Recently, a series of mutually exclusive mutations that affect TET2, IDH1 or IDH2 mutations, and potentially other as of yet unidentified disease alleles, was reported. 27, 34 We observed the same pattern of mutual exclusiveness in our series and additionally between IKAROS genes.
Correlation between epigenetic modifier mutations and prognosis has been controversial. TET2 mutations are associated with poor prognosis in normal karyotype-AML, 35 but with no clear association in myelodysplastic syndromes 36 or myeloproliferative neoplasm. 37 Alterations in IDH1/2 are associated with a favorable or negligible effect on prognosis, depending on the type of mutation in AML. 38, 39 No importance was observed in myelodysplastic syndromes 36 or myeloproliferative neoplasm. 37, 40 Several studies show that DNMT3A mutations are associated with worsened OS in patients with AML 41, 42 and an adverse prognosis in myelodysplastic syndromes. 43 In our series of BPDCN patients, we found that patients with mutations in genes in methylation pathways had a significantly reduced OS as compared with individuals without mutations in these genes. These data suggest that mutations in DNA methylation genes represent a poor prognostic factor that are likely to be involved in the pathogenesis of BPDCN.
Changing the paradigm of what is known about BPDCN, our data suggest that this dendritic cell leukemia has a mutational profile strikingly similar to that of other well-defined myeloid leukemias. Despite the numerous advances in our understanding of the genetics and epigenetics of myeloid malignancies, only limited examples of clinical translation of these findings into new therapeutic approaches have been implemented. However, it has now become clear that the epigenetic modifiers provide new targets for therapeutic intervention and that targeting these enzymatic activities are currently being explored from a therapeutic standpoint in several types of leukemia. 44, 45 Our study provides, for the first time, molecular data that suggest that a complete and innovative change is required in the treatment approach adopted for patients with BPDCN, including the administration of drugs that target aberrant methylation, chromatin remodeling, specific transcription factors and aberrant splicing.
